New hope for pancreatic cancer? drug combo trial launches
NCT ID NCT06844422
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called ivonescimab, combined with targeted radiation and chemotherapy, for people with locally advanced pancreatic cancer that cannot be removed by surgery. The trial has two phases: first, finding the safest dose of ivonescimab, then checking how well the combination works at controlling the cancer. About 37 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ivonescimab (a drug that targets PD-1 and VEGF, combined with radiation and chemotherapy)
What this could lead to
If successful, this could offer a new treatment option for people with locally advanced pancreatic cancer, potentially slowing tumor growth and improving survival.
What could go wrong
This is an early-phase trial with only 37 participants, so results may not apply to everyone. The combination therapy may cause significant side effects, and the drug may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Cancer Hospital and Institute
RECRUITINGJinan, Shandong, 0531, China
Contact Phone: •••-•••-•••• Email: •••••@•••••